Скачать или смотреть Dr. Steven Quay MD, Ph.D. CEO of Atossa Therapeutics (NASDAQ: ATOS) Webinar Event July 30, 2020

DISCLAIMER: https://www.tribepublic.com/disclaimers

Tribe Public's Managing Partner, John F. Heerdink, Jr. hosted a Webinar Presentation and Q&A Event with Dr. Steven Quay MD, Ph.D., Chairman, CEO, and Founder of Atossa Therapeutics (NASDAQ: ATOS) on Wednesday, July 30th, 2020 at 8 am pacific to 8:30 am pacific.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. He received his M.D. and Ph.D. from The University of Michigan was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, and a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. His current passions are big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancers in the world each year. His website is www.drquay.com

He also recently published the following book “Your COVID-19 Survival Manual: A Physician’s Guide to Keep You and Your Family Healthy During the Pandemic and Beyond,” and will be offering a significant discount code to all that will be attending his Tribe Zoom Webinar meeting on July 30th. Proceeds from the book will go to military veterans performing COVID-19 relief work in their communities. You may order it ahead of time at www.drquay.com.

Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19.

Atossa believed their innovative therapies and delivery methods can benefit COVID-19 patients and transform breast cancer treatment – with the goal of preventing breast cancer from developing in the first place.

They have two COVID-19 therapeutic programs under development, one for severely ill patients on ventilators and another for at-home use in patients recently diagnosed with COVID-19 who do not require hospitalization.

They are also developing a drug “endoxifen” to reduce mammographic breast density and, for patients who have recently been diagnosed with the most common type of breast cancer, to reduce tumor activity prior to surgery. Approximately one in eight women and one in 1,000 men will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. The American Cancer Society (ACS) estimates that approximately 270,000 women will be diagnosed with breast cancer in the United States this year. It is the second leading cause of cancer death in American women.